Scientific Program Sunday 2 December, 2012 10:00 – 12:00 Parkside G04 PGx: new research interests and directions workshop 14:30 – 16:30 Parkside 110A Parkside G04 Parkside 110B ASCEPT-APSA Careers workshop ASCEPT-APSA Clinical ASCEPT-APSA Education Careers in the pharmaceutical industry Pharmacology workshop Forum workshop Chairs Dr Barbara Kemp-Harper, Introduction to TDM/TCI Introduction and scene setting; TEQSA; Ms Claire Johnston, Ms Alice Kane Dr Matt Doogue Standards Panel and TLOs Finding your way in the Pharmaceutical Measuring drug concentrations, analytical Prof Ieva Stupans, University of New Industry methods and issues England Dr Annette Gross, GlaxoSmithKline R&D Dr Andrew Rowland Mapping assessment to TLOs for pharmacy It’s a long way from rats and lab coats Digoxin, a classic Prof Ieva Stupans, University of New Dr Richard Booth, iNOVA Pharmaceuticals Prof Ray Morris England What I wish I knew about clinical trials The perhexiline story What is the relevance of TLOs for the roles and networking when I was sitting Prof John Horowitz teaching of pharmacology? where you are today! Dr Liz Davis, Monash University and Dr Dr Craig Rayner, Roche Tina Hinton, The University of Sydney How to locate and maximise your success in finding your ideal job Dr Amanda Reid, Daryl Alexander & Associates 17:00 – 18:00 Parkside Auditorium Welcome to country Opening session and plenary 1 Prof David Le Couteur, ASCEPT President Prof Andrew McLachlan, APSA President Emeritus Prof Kim Oates AM, The University of Sydney 18:00 – 19:30 Welcome Reception Parkside Foyer, Level 1 Monday 3 December, 2012 08:00 – 09:00 Parkside Foyer, Level 1 Poster presentations SPONSORED BY 09:00 – 10:00 Parkside Auditorium Plenary 2: British Pharmacological Society lecture Proton pump inhibitors - robust evidence of public health hazard, or just plain confounding? - 101 Dr Yoon Loke, The University of East Anglia, UK 10:00 – 10:30 Morning tea 10:30 – 12:30 Parkside Auditorium Parkside 110A Parkside 110B Parkside G04 Symposium 1: Symposium 2: Symposium 3: Symposium 4: Drug transporters in clinical The yin and yang of novel Emerging trends in dose The patient journey pharmacokinetics and drug-drug receptor drug discovery individualisation in clinical interactions paradigms practice Chairs Dr Joseph Nicolazzo Dr Meritxell Canals Buj A/Prof Ross Norris Prof Ines Krass A/Prof Betty Sallustio Transporter-based drug-drug Inflammation resolution Non-parametric population The patient journey towards the interactions – principles and mediators in tumour growth PK models and their use in end of life-patient and family examples - 102 and metastasis: good, bad and individual patient care - 110 accounts of patient safety - 114 Prof Jashvant Unadkat, indifferent - 106 A/Prof Michael Neely, University Ms Aileen Collier, Centre University of Washington, USA Prof Alastair Stewart, The of Southern California, USA for Health Communication, Role of organic cation University of Melbourne Emerging trends in dose University of Technology Sydney transporters in mediating oral Exploring allosteric modulation individualisation in clinical Towards a medicinewise drug absorption - 103 and ligand-directed stimulus practice - 111 Australia: the NPS approach to Dr Dhiren Thakker, University of bias at the glucagon-like A/Prof Jennifer Martin, The improving health literacy - 115 North Carolina, USA peptide-1 receptor - 107 University of Queensland Ms Karen Kaye, NPS Role of transporters in mediating Denise Wootten, Monash Pharmacogenomics in dose Medicinewise hepatobiliary clearance of drugs University individualisation - 112 - 104 Physiological correlates of Prof Elizabeth Phillips, Institute Prof Kim Brouwer, University of biased receptor signalling: for Immunology & Infectious North Carolina, USA relevance to opioid drug action Diseases Impact of BBB Transporters in health and disease - 108 Dose individualisation of on Delivery and Efficacy of Dr Laura Bohn, The Scripps Dabigatrin - 113 Molecularly-Targeted Agents in Research Institute, Florida, USA Dr Paul Chin, University of Brain Tumors - 105 Revealing the potential of GPCR Otago, NZ Prof William Elmquist, University bias signalling - 109 of Minnesota, USA Prof Andrew Tobin, University of Leicester, UK 1 Monday 3 December, 2012 cont. 12:30 – 13:30 Parkside Foyer, Level 1 Lunch and poster presentations Parkside Auditorium Parkside G04 Parkside 110B Parkside 110A Meetings: Pharmacogenomics SIG New Zealand Forum Toxicology and Drug Discovery Neuro- behavioural SIG SIG 13:30 – 15:30 Parkside 110B Parkside Auditorium Parkside G04 Parkside 110A Oral presentations 1 Oral presentations 2 Oral presentations 3: Oral presentations 4 Clinical Trainee Chairs Dr Betty Exintaris A/Prof Lynne Emmerton Dr Matt Doogue Dr David Shackleford 13:30 – 13:45 The effect of ageing on What parents want to know about Is the process for approval of Differential effects of mango paracetamol pharmacokinetics attention-deficit hyperactivity high cost drugs for off-formulary peel sub-fractions on lipid and toxicity in Fischer 344 rats disorder (ADHD)- A qualitative use leading to clinically accumulation in 3T3-L1 - 120 investigation - 128 appropriate outcomes? - 136 adipocyte cells - 144 Mr John Mach, Kolling Institute Miss Rana Ahmed, The Faculty Dr Catherine Lucas, Department Mr Meng-Wong Taing, School of Medical Research, Royal of Pharmacy, The University of of Clinical Pharmacology, Royal of Pharmacy, The University of North Shore Hospital, Sydney Sydney Brisbane and Women’s Hospital Queensland Medical School, The University of Sydney 13:45 – 14:00 NOX2ß: A Novel Splice Variant The influence of disease and The performance of the The preparation and of NOX2 That Promotes other factors on adherence - 129 Cockcroft-Gault, MDRD and characterisation of polypyrrole Reactive Oxygen Species (ROS) Miss Piyanan CKD-EPI equations in predicting particles for tuneable drug Production in Macrophages - Assawasuwannakit, School of gentamicin clearance - 137 delivery - 145 121 Pharmacy, University of Otago, Dr Paul Chin, Department Mr Zaid Aqrawe, The University Dr Stavros Selemidis, NZ of Clinical Pharmacology, of Auckland, NZ Department of Pharmacology, Christchurch Hospital, NZ, Monash University Department of Medicine, University of Otago, NZ 14:00 – 14:15 Bitter taste receptor agonists are Strategies used to support Describing the use of antibiotics Characterisation of emulsions novel bronchodilators of small patients’ adherence to in acute exacerbations of as potential saliva substitutes in airways in mouse lung slices medication: a national survey of chronic obstructive pulmonary xerostomia - 146 - 122 community pharmacists - 130 disease - 138 Miss Sara Hanning, School of Dr Jane Bourke, Dept of Mrs Sarab Mansoor, Faculty of Dr Mitchell McKean, Princess Pharmacy, University of Otago, Pharmacology, University of Pharmacy, The University of Alexandra Hospital NZ Melbourne Sydney 14:15 – 14:30 Screening potential skin Beyond expectations? Do Cytochrome P450 2C19 Conformational stability of sensitizers using high throughput pharmacists perform clinical genotyping cost-effective for various proteins in solid lipid direct peptide activity assay - interventions when carrying out guiding clopidogrel treatment in matrices prepared by melting 123 adherence support medication Australia - 139 and cooling - 147 Dr Sussan Ghassabian, Centre reviews? - 131 Dr Michael Sorich, Sansom Mr Farrukh Zeeshan, School of for Integrated Preclinical Drug Dr Rhiannon Braund, School of Institute, University of South Pharmacy, University of Otago, Development, University of Pharmacy, University of Otago, Australia NZ Queenland NZ 14:30– 14:45 The antimicrobial peptide LL-37 Asthma management in Liver Transplant Donor and PEGylated surfactants inhibit inhibits migration of the prostate intellectual disability (ID) - Recipient CYP3A5 and ABCB1 the digestion of co-formulated cancer cells - 124 identifying opportunities for the Genetics and Tacrolimus triglycerides in a PEG chain Ms Yan Tu, Department of pharmacist - 132 Pharmacokinetics - 140 length dependent manner - 148 Pharmacology, University of Mrs Sharon Davis, Faculty of Dr Janet Coller, Disc Miss Orlagh Feeney, Faculty of Melbourne Pharmacy, The University of Pharmacology, University of Pharmacy and Pharmaceutical Sydney Adelaide Sciences, Monash University 14:45 – 15:00 Expression and localisation Effects of three different forms Pro-migratory actions of The lymphatic system is of Pannexin-1 Hemichannels of inhaler technique education prostacyclin in breast cancer critical in maintaining the in human colon in health and for health care professionals on cells that over-express prolonged circulation of disease - 125 patient asthma outcomes - 133 cyclooxygenase-2 - 141 monoclonal antibodies and in Miss Erica Diezmos, Depts Dr Sinthia Bosnic-Anticevich, Dr Sarah Allison, promoting absorption from the of Pharmacology, School of The University of Sydney Pharmacogenomics and subcutaneous injection site - Medical Sciences, University of Drug Development, Faculty of 149 New South Wales Pharmacy, The University of Ms Annette Dahlberg, Monash Sydney Institute of Pharmaceutical Sciences, Monash University 15:00 – 15:15 Neurokinin A potentiates Community pharmacy as a A new pharmacokinetic Stabilisation of amorphous spontaneous and purinergic health hub: meeting the needs of abnormality among patients with indomethacin in aqueous evoked smooth muscle people with chronic conditions 5-fluorouracil toxicity - 142 suspensions: Effect of polymer contraction and